flutamide has been researched along with Diarrhea in 10 studies
Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Diarrhea: An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a recent study by the Casodex Combination Study Group, USA, patients in a flutamide (750 mg/day) plus LH-RH agonist group showed a high treatment failure rate, mainly due to flutamide-induced diarrhea and hepatotoxicity." | 5.08 | Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer. ( Akaza, H; Aso, Y; Isaka, S; Kanetake, H; Koiso, K; Kotake, T; Usami, M, 1996) |
| " Cross-sectional analyses (corrected for multiple testing) identified statistically significant differences that favored orchiectomy plus placebo for two of the five primary QOL parameters as follows: patients receiving flutamide reported more diarrhea at 3 months (P = ." | 5.08 | Quality of life in advanced prostate cancer: results of a randomized therapeutic trial. ( Blumenstein, BA; Crawford, ED; Eisenberger, M; Higgins, B; Lovato, LC; Meyskens, FL; Moinpour, CM; Savage, MJ; Skeel, R; Troxel, A; Veith, RW; Yee, M, 1998) |
| "Flutamide was administered in monotherapy (75 patients (8%)) or as part of total androgen blockade (TAB groups): the latter group had orchiectomy (196 patients (22%)) or an LHRH (634 patients (70%))." | 2.68 | Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. A Belgian multicenter study of 905 patients. ( Casselman, J; Kurjatkin, O; Mattelaer, J; Oosterlinck, W; Schulman, C; Van Velthoven, R, 1996) |
| "Flutamide was given by mouth in a dose of 250 mg t." | 2.67 | Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy. ( Hwang, YS; John, MJ; Krall, JM; McGowan, D; Perez, CA; Pilepich, MV, 1990) |
| "The present data suggest that those prostate cancer patients who have even marginally elevated adrenal androgens may especially benefit from combined androgen blockade." | 1.35 | Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists. ( Belanger, A; Chertin, B; Farkas, A; Fridmans, A; Hartman, H; Labrie, F; Spitz, IM, 2009) |
| "Treatment choices for metastatic prostate cancer are complex and can involve men balancing survival versus quality of life." | 1.35 | Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. ( Dewilde, S; Kleinman, L; Lloyd, A; Penson, D, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 6 (60.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Spitz, IM | 1 |
| Chertin, B | 1 |
| Fridmans, A | 1 |
| Farkas, A | 1 |
| Belanger, A | 1 |
| Hartman, H | 1 |
| Labrie, F | 1 |
| Miller, NL | 1 |
| Bissonette, EA | 1 |
| Bahnson, R | 1 |
| Wilson, J | 1 |
| Theodorescu, D | 1 |
| Lloyd, A | 1 |
| Penson, D | 1 |
| Dewilde, S | 1 |
| Kleinman, L | 1 |
| Aso, Y | 2 |
| Akaza, H | 2 |
| Koiso, K | 2 |
| Kameyama, S | 1 |
| Koyanagi, T | 1 |
| Kawai, T | 1 |
| Kumamoto, Y | 1 |
| Tazaki, H | 1 |
| Funyu, T | 1 |
| Oshima, H | 1 |
| Oosterlinck, W | 1 |
| Casselman, J | 1 |
| Mattelaer, J | 1 |
| Van Velthoven, R | 1 |
| Kurjatkin, O | 1 |
| Schulman, C | 1 |
| Isaka, S | 1 |
| Usami, M | 1 |
| Kanetake, H | 1 |
| Kotake, T | 1 |
| Moinpour, CM | 1 |
| Savage, MJ | 1 |
| Troxel, A | 1 |
| Lovato, LC | 1 |
| Eisenberger, M | 1 |
| Veith, RW | 1 |
| Higgins, B | 1 |
| Skeel, R | 1 |
| Yee, M | 1 |
| Blumenstein, BA | 1 |
| Crawford, ED | 2 |
| Meyskens, FL | 1 |
| Pilepich, MV | 1 |
| John, MJ | 1 |
| Krall, JM | 1 |
| McGowan, D | 1 |
| Hwang, YS | 1 |
| Perez, CA | 1 |
| Yagoda, A | 1 |
6 trials available for flutamide and Diarrhea
| Article | Year |
|---|---|
[Clinical evaluation of flutamide, a pure antiandrogen, in prostatic cancer phase II dose-finding study].
Topics: Administration, Oral; Aged; Aged, 80 and over; Diarrhea; Drug Administration Schedule; Flutamide; Fo | 1993 |
Tolerability and safety of flutamide in monotherapy, with orchiectomy or with LHRH-a in advanced prostate cancer patients. A Belgian multicenter study of 905 patients.
Topics: Appetite; Combined Modality Therapy; Diarrhea; Flutamide; Gonadotropin-Releasing Hormone; Humans; Li | 1996 |
Recommended dose of flutamide with LH-RH agonist therapy in patients with advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemical and Drug In | 1996 |
Quality of life in advanced prostate cancer: results of a randomized therapeutic trial.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Cross-Section | 1998 |
Combination studies with leuprolide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Double-Blind Method; Flutamide; Gonadotrop | 1990 |
Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy.
Topics: Buserelin; Diarrhea; Flutamide; Goserelin; Humans; Male; Prostatic Neoplasms; Radiotherapy | 1990 |
4 other studies available for flutamide and Diarrhea
| Article | Year |
|---|---|
Partial androgen suppression consequent to increased secretion of adrenal androgens in a patient with prostate cancer treated with long-acting GnRH agonists.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Androgens; Anilides; Buserelin; Diarrhea; Flutamide; Gas | 2009 |
Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy.
Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Brachytherapy; C | 2003 |
Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Choice Behavi | 2008 |
Flutamide-induced diarrhea secondary to lactose intolerance.
Topics: Aged; Anilides; Diarrhea; Flutamide; Humans; Lactose Intolerance; Male; Middle Aged | 1989 |